| DB ID | MyCo_3152 |
| Title | Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies |
| Year | 2018 |
| PMID | 29693758 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | Neutropenic patients with haematological malignancies |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | This single-¬ centre retrospective study was conducted at the Haematology Division of Ospedale Policlinico San Martino, a 1200-bed teaching hospital in Genoa, Italy. During the study period, 171 patients met the study inclusion cri-teria. Of them, 4 (2%) were excluded from the analyses because of other IFD (all candidaemia). Of note, BDG was <80 pg/mL in all the excluded patients with candidaemia. Overall, 167 patients were included in the analysis. Their median age was 58 years (range: 20-¬ 98) and 100 were male (60%). |
| Cohort No. | 167 |
| Age Group | -20 |
| P Value | None |
| Sensitivity | 0.4 |
| Specificity | 0.93 |
| Positive Predictive Value | 0.44 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) remains an important cause of morbidity and mortality in neutropenic haematology patients. Early diagno-sis of IA is fundamental for prompting early treatment and improving outcome, but it is rarely achieved through the standard mycologi-cal approach, which requires microscopy, histology, and/or culture from normally sterile materials. Indeed, these techniques have low sensitivity (culture) and limited feasibility (biopsy) due to the risk of bleeding in thrombocytopenic patients. |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | ELISA Kit- Platelia Aspergillus; Bio‐Rad laboratories, Marnes‐la- Coquette, France |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay, FDA Approved -Platelia Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
